Target Name: RNASEH1-DT
NCBI ID: G100506054
Review Report on RNASEH1-DT Target / Biomarker Content of Review Report on RNASEH1-DT Target / Biomarker
RNASEH1-DT
Other Name(s): RNASEH1-AS1 | RNASEH1 divergent transcript | RNASEH1 divergent transcript, transcript variant 1 | RNASEH1-DT variant 1

RNASEH1-DT: A Drug Target / Disease Biomarker

RNA-Nucleic Acid Enzyme Homolog (RNA-NHEH1) is a protein that is expressed in various cell types of the human body, including the liver, lung, and pancreas. It plays a crucial role in the regulation of gene expression and has been linked to a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the unique features of RNA-NHEH1 is its ability to interact with DNA and RNA to regulate gene expression. This protein has been shown to play a role in the regulation of gene expression by binding to specific DNA sequences and modulating the activity of transcription factors. In addition, RNA-NHEH1 has also been shown to play a role in the regulation of RNA stability and degradation, which is important for the efficient translation of RNA into proteins.

RNA-NHEH1 has also been shown to be involved in a number of cellular processes that are important for human health, including the regulation of inflammation, DNA replication, and cell apoptosis. For example, RNA-NHEH1 has been shown to play a role in the regulation of inflammation, by participating in the production of immune responses and modulating the activity of immune cells. In addition, RNA-NHEH1 has also been shown to play a role in the regulation of DNA replication, by binding to specific DNA sequences and modulating the activity of DNA replication factors.

In addition to its role in cellular processes, RNA-NHEH1 has also been shown to be involved in a number of diseases, including cancer. For example, RNA-NHEH1 has been shown to play a role in the regulation of gene expression in cancer cells, by binding to specific DNA sequences and modulating the activity of transcription factors. In addition, RNA-NHEH1 has also been shown to play a role in the regulation of cell apoptosis, which is the process by which cells undergo programmed cell death.

Given its involvement in a number of cellular processes that are important for human health, RNA-NHEH1 has been identified as a potential drug target. Researchers have been studying the use of RNA-NHEH1 as a drug target, in order to understand its role in disease and to identify potential new treatments for a number of diseases.

One approach that researchers have been studying is the use of RNA-NHEH1 inhibitors to treat diseases. Researchers have been shown that RNA-NHEH1 inhibitors can be effective in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, researchers have shown that RNA-NHEH1 inhibitors can be effective in inhibiting the growth of cancer cells and slowing the progression of neurodegenerative diseases.

Another approach that researchers have been studying is the use of RNA-NHEH1 activators to treat diseases. Researchers have been shown that RNA-NHEH1 activators can be effective in stimulating the production of immune cells and modulating the activity of immune cells. For example, researchers have shown that RNA-NHEH1 activators can be effective in treating cancer by stimulating the production of immune cells that can recognize and attack the cancer cells.

In conclusion, RNA-NHEH1 is a protein that is expressed in various cell types of the human body and plays a crucial role in the regulation of gene expression, as well as the regulation of DNA replication and cell apoptosis. Its unique ability to interact with DNA and RNA to regulate gene expression and its involvement in a number of diseases make it an attractive target for research and treatment. The use of RNA-NHEH1 inhibitors and activators has the potential to revolutionize the treatment of a wide range of diseases.

Protein Name: RNASEH1 Divergent Transcript

The "RNASEH1-DT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RNASEH1-DT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

RNASEH2A | RNASEH2B | RNASEH2B-AS1 | RNASEH2C | RNASEH2CP1 | RNASEK | RNASEL | RNASET2 | RND1 | RND2 | RND3 | RNF10 | RNF103 | RNF103-CHMP3 | RNF11 | RNF111 | RNF112 | RNF113A | RNF113B | RNF114 | RNF115 | RNF121 | RNF122 | RNF123 | RNF125 | RNF126 | RNF126P1 | RNF128 | RNF13 | RNF130 | RNF133 | RNF135 | RNF138 | RNF138P1 | RNF139 | RNF139-DT | RNF14 | RNF141 | RNF144A | RNF144B | RNF145 | RNF146 | RNF148 | RNF149 | RNF150 | RNF151 | RNF152 | RNF157 | RNF157-AS1 | RNF165 | RNF166 | RNF167 | RNF168 | RNF169 | RNF17 | RNF170 | RNF175 | RNF180 | RNF181 | RNF182 | RNF183 | RNF185 | RNF186 | RNF187 | RNF19A | RNF19B | RNF2 | RNF20 | RNF207 | RNF208 | RNF212 | RNF212B | RNF213 | RNF213-AS1 | RNF214 | RNF215 | RNF216 | RNF216-IT1 | RNF216P1 | RNF217 | RNF217-AS1 | RNF220 | RNF222 | RNF224 | RNF225 | RNF227 | RNF24 | RNF25 | RNF26 | RNF31 | RNF32 | RNF32-DT | RNF34 | RNF38 | RNF39 | RNF4 | RNF40 | RNF41 | RNF43 | RNF44